REGINA — People in Saskatchewan living with cystic fibrosis (CF) are now eligible for Alyftrek, a medication that improves lung function.
As of Aug. 1, coverage of Alyftrek is now available to CF patients ages six and older who meet the medical criteria. The drug is effective for patients who have one of 266 different rare genetic mutations causing CF.
Although there is no cure for CF, Alyftrek controls symptoms and slows the rate at which the disease progresses.
Coverage comes after Health Canada issued a recommendation in July 2025 that jurisdictions cover Alyftrek for patients six years of age and older who meet certain medical criteria, followed by successful pricing negotiations through the pan-Canadian Pharmaceutical Alliance in July 2026.
Saskatchewan also provides coverage for other CF medications that treat specific genetic forms of the disease, including Trikafta, Orkambi and Kalydeco. The additional listing of Alyftrek expands access to effective CF treatment, making more than 95 per cent of eligible patients in Saskatchewan candidates for the therapy.
Patients with CF or parents/guardians of children with CF who think they may benefit from therapy with Alyftrek are encouraged to speak with their physician.
CF is a genetic disease that damages the lungs and digestive system. According to the Canadian Cystic Fibrosis Registry, there are more than 4,500 CF patients in Canada and almost 150 patients in Saskatchewan.
